10.25
price up icon0.49%   0.05
 
loading
Precedente Chiudi:
$10.20
Aprire:
$10.2
Volume 24 ore:
60,915
Relative Volume:
0.85
Capitalizzazione di mercato:
$299.91M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-6.0294
EPS:
-1.7
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
+11.53%
1M Prestazione:
+61.42%
6M Prestazione:
+36.12%
1 anno Prestazione:
+15.69%
Intervallo 1D:
Value
$9.79
$10.46
Intervallo di 1 settimana:
Value
$8.76
$10.77
Portata 52W:
Value
$5.45
$18.15

Neuropace Inc Stock (NPCE) Company Profile

Name
Nome
Neuropace Inc
Name
Telefono
(650) 237-2700
Name
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Name
Dipendente
184
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
NPCE's Discussions on Twitter

Confronta NPCE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Medical Devices icon
NPCE
Neuropace Inc
10.25 299.91M 65.42M -32.96M -19.87M -1.70
Medical Devices icon
ABT
Abbott Laboratories
118.95 208.18B 41.22B 5.77B 6.49B 2.94
Medical Devices icon
SYK
Stryker Corp
388.14 148.70B 21.97B 3.59B 3.21B 6.74
Medical Devices icon
BSX
Boston Scientific Corp
90.75 133.32B 15.91B 1.79B 1.89B 0.82
Medical Devices icon
MDT
Medtronic Plc
86.27 111.27B 33.00B 4.29B 5.50B 2.71
Medical Devices icon
EW
Edwards Lifesciences Corp
72.07 42.66B 6.60B 4.16B 490.10M 2.34

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-03-14 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-01-30 Iniziato Leerink Partners Outperform
2023-11-10 Iniziato Cantor Fitzgerald Overweight
2023-08-24 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-02-22 Iniziato Lake Street Buy
2022-04-06 Iniziato Wolfe Research Outperform
2022-01-19 Downgrade Wells Fargo Overweight → Equal Weight
2022-01-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-11-11 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-08-18 Iniziato Robert W. Baird Outperform
2021-05-17 Iniziato JP Morgan Overweight
2021-05-17 Iniziato Morgan Stanley Overweight
2021-05-17 Iniziato SVB Leerink Outperform
2021-05-17 Iniziato Wells Fargo Overweight
Mostra tutto

Neuropace Inc Borsa (NPCE) Ultime notizie

pulisher
Nov 25, 2024

NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.60 Average PT from Analysts - MarketBeat

Nov 25, 2024
pulisher
Nov 21, 2024

NeuroPace, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024
pulisher
Nov 21, 2024

Top 10 Deep Brain Stimulation Device Companies | Provides Best DevicesMarket.us Media - Market.us Media - United States Market News

Nov 21, 2024
pulisher
Nov 21, 2024

NeuroPace (NASDAQ:NPCE) versus Cerus (NASDAQ:CERS) Financial Analysis - Defense World

Nov 21, 2024
pulisher
Nov 20, 2024

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

What Makes NeuroPace (NPCE) a New Buy Stock - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

NeuroPace FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

NeuroPace (NASDAQ:NPCE) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World

Nov 17, 2024
pulisher
Nov 16, 2024

FY2024 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

NeuroPace FY2024 EPS Forecast Boosted by Leerink Partnrs - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

NeuroPace Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results - Simply Wall St

Nov 14, 2024
pulisher
Nov 14, 2024

Long NPCE: NeuroPace Inc. Q3 Earnings, 28% Revenue Growth, Nautilus Study Progress, and Breakout from $6-$7 Consolidation Signal Bullish Momentum - Invezz

Nov 14, 2024
pulisher
Nov 14, 2024

How the (NPCE) price action is used to our Advantage - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 13, 2024

NeuroPace price target lowered to $13 from $15 at Wells Fargo - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

500: Something went wrong - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance - The Manila Times

Nov 13, 2024
pulisher
Nov 12, 2024

NeuroPace, Inc. Reports Strong Q3 2024 Results - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

NeuroPace Inc.: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 12, 2024
pulisher
Nov 12, 2024

Neuropace earnings beat by $0.08, revenue topped estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider - GlobeNewswire Inc.

Nov 11, 2024
pulisher
Nov 11, 2024

Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result - Yahoo Finance

Nov 11, 2024
pulisher
Nov 10, 2024

NeuroPace (NPCE) Set to Announce Earnings on Tuesday - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

private equity firms who own 45% along with institutions invested in NeuroPace, Inc. (NASDAQ:NPCE) saw increase in their holdings value last week - Yahoo Finance

Nov 09, 2024
pulisher
Nov 07, 2024

Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet? - Simply Wall St

Nov 07, 2024
pulisher
Nov 06, 2024

NeuroPace submits RNS System study data to FDA By Investing.com - Investing.com Australia

Nov 06, 2024
pulisher
Nov 05, 2024

NeuroPace (NPCE) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy - ForexTV.com

Nov 04, 2024
pulisher
Nov 04, 2024

NeuroPace submits RNS System study data to FDA - Investing.com India

Nov 04, 2024
pulisher
Nov 03, 2024

How to Take Advantage of moves in (NPCE) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 03, 2024

Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $14.00 - Defense World

Nov 03, 2024
pulisher
Oct 31, 2024

NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Deep Brain Stimulation Devices Market Growing Popularity & Emerging Trends | Medtronic, NeuroPace, LivaNova - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Neuropace shareholder KCK Ltd. sells $1.22 million in stock By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Neuropace shareholder KCK Ltd. sells $1.22 million in stock - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

KCK LTD. Adjusts Stake in NeuroPace Inc - GuruFocus.com

Oct 24, 2024
pulisher
Oct 24, 2024

Neuropace Inc sees $24,853 stock sale by major shareholder - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Page 85 – Impact Investing - Equities News

Oct 24, 2024
pulisher
Oct 23, 2024

Neuropace stock hits 52-week low at $5.66 amid market challenges - Investing.com Australia

Oct 23, 2024

Neuropace Inc Azioni (NPCE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Neuropace Inc Azioni (NPCE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
KCK LTD.
10% Owner
Oct 23 '24
Sale
6.02
147
885
5,494,836
medical_devices STE
$217.47
price up icon 0.65%
medical_devices ZBH
$112.02
price up icon 1.25%
medical_devices PHG
$27.15
price up icon 0.89%
$78.10
price up icon 0.21%
$83.00
price up icon 0.59%
medical_devices EW
$72.07
price up icon 0.73%
Capitalizzazione:     |  Volume (24 ore):